Sissetulev kiriAvalik
Farmakopöa töökava asjus
Ravimiamet · 27. jaanuar 2025
- Viit
- REP-1/396-1
- Registreeritud
- 27. jaanuar 2025
- Dokumendi liik
- Sissetulev kiri
- Adressaat
- European Directorate for the Quality of Medicines & HealthCare
- Saabumis/saatmisviis
- e-post
- Funktsioon
- REP Euroopa Farmakopöaga seotud asjaajamine
- Sari
- REP-1 Euroopa Farmakopöa alane kirjavahetus
- Toimik
- REP-1/2025
- Vastutaja
- Signe Leito (RA, Peadirektori asetäitja valdkond, Labor)
Sisu (failidest)
Signe Leito
Saatja: [email protected]
Saatmisaeg: neljapäev, 23. jaanuar 2025 10:25
Adressaat: Signe Leito
Teema: Survey: Proposed addition to the work programme P4: Pitolisant hydrochloride and Pitolisant hydrochloride tablets: EDQM-2025-00340-
mail
Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada.
Please make sure to include in any reply our mail reference: EDQM-2025-00340-mail
****************************************************************************
For the attention of NPAs
Copy: Presidium
Dear Colleagues,
Please find below the link to a survey being carried out concerning the proposed addition of Pitolisant hydrochloride and Pitolisant hydrochloride tablets to the work
programme P4.
In order to have access to the survey, please copy and paste this link into your Internet browser:
https://survey.edqm.eu/index.php?r=survey/index&sid=437182&newtest=Y&lang=en
Deadline for replies: 25 February 2025. Thank you.
With kind regards
On behalf of Monica Sorinas Jimeno
___
Villy Nikolova
Administrative Support Assistant
European Pharmacopoeia Department
EDQM
Council of Europe
1
Tel.: +33 (0)3 90 21 64 63 / Fax: +33 (0)3 88 41 27 71
https://www.edqm.eu / https://www.edqm.eu/store
Stay connected with the EDQM
Confidentiality Notice:
This e-mail and any attached files may contain confidential information that is intended only for the addressee(s). If you are not the intended recipient, you are hereby notified that any
disclosure, copying, distribution, or reliance upon the contents of this e-mail (including any attached files) is strictly prohibited. Anyone who receives this message in error should notify the
sender immediately by using the reply function and then permanently delete this e-mail (including any attached files). Thank you.
****************************************************************************
Please make sure to include in any reply our mail reference: EDQM-2025-00340-mail
2